Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: Expert Rev Vaccines. 2009 Apr;8(4):469–481. doi: 10.1586/erv.09.1

Figure 3. Schema for mass production of Ad5-vectored avian influenza (AI) vaccines.

Figure 3

PER.C6 suspension cells are propagated in serum-free medium in a disposable cellbag on a WAVETM bioreactor; Ad5-infected cells are lysed by treatment with a detergent; PER.C6 DNA is digested with benzonase; Ad5 particles are purified by anion exchange chromatography and formulated in A195 buffer [87]; and the Ad5-vectored AI vaccine is finally sterilized by filtration through 0.2-µm membranes. This schema was a modification of that for producing cGMP-grade Ad5-vectored AI vaccines in one of Vaxin’s Investigational New Drug applications filed with the US FDA.

Ad5: Adenovirus serotype 5.